Letter Agreement, dated September 3, 2020, with Qorvo Biotechnologies, LLC
Exhibit 10.10
 | 18683 Bearpath Trail |
Eden Prairie, MN 55347
Telephone ###-###-####
***@***
Robert Cohen
Chief Executive Officer
September 3, 2020
Mr. Hanjoon Ryu
General Manager
Qorvo Biotechnologies, LLC
14205 21st Avenue North (Suite 212)
Plymouth, MN 55447
Dear Hanjoon:
In partial fulfillment of the final Milestone Event set forth in Section 6.1 of the Development and Supply Agreement between Qorvo Biotechnologies, LLC ("Qorvo") and Zomedica Pharmaceuticals Corp. ("Zomedica") dated November 26, 2018 (the "Original Agreement") and amended August 14, 2020, Zomedica hereby identifies the sixth and seventh assays to be developed pursuant to Section 3.4 of the Original Agreement as follows:
| Assay #6: | Canine Pancreatic Lipase (cPL) - Pancreatic Biomarker | |
| Species: | Canine | |
| Matrix: | Serum | |
| Assay #7: | Cobalamin (Vitamin B12) - Distal Small Intestine Biomarker | |
| Species: | Canine | |
| Matrix: | Serum |
In addition, we have identified the eighth assay to be developed with Assay #6 and Assay #7 above in order to comprise a complete gastrointestinal panel:
| Assay #8: | Folate (Vitamin B9) - Proximal Small Intestine Biomarker | |
| Species: | Canine | |
| Matrix: | Serum |
If you are in agreement with the above, kindly sign and return this document to me. We then will forward the $2 million milestone payment promptly.
Best regards,
/s/ Robert Cohen
Robert Cohen
AGREED TO AND ACCEPTED BY:
Qorvo Biotechnologies, LLC
| Signature: | /s/ Hanjoon Ryu | ||
| Name: | Hanjoon Ryu | ||
| Date: | September 4, 2020 |
